Dmitry V Shcheblyakov

InstitutionN F Gamaleya National Research Centre for Epidemiology and Microbiology
AddressRussia
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 6 Covid-19 publications, with a maximum of 2 publications in Spetember 2020
    All Publications
    Bar chart showing 13 publications over 8 distinct years, with a maximum of 4 publications in 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Gushchin VA, Dolzhikova IV, Shchetinin AM, Odintsova AS, Siniavin AE, Nikiforova MA, Pochtovyi AA, Shidlovskaya EV, Kuznetsova NA, Burgasova OA, Kolobukhina LV, Iliukhina AA, Kovyrshina AV, Botikov AG, Kuzina AV, Grousova DM, Tukhvatulin AI, Shcheblyakov DV, Zubkova OV, Karpova OV, Voronina OL, Ryzhova NN, Aksenova EI, Kunda MS, Lioznov DA, Danilenko DM, Komissarov AB, Tkachuck AP, Logunov DY, Gintsburg AL. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines (Basel). 2021 Jul 12; 9(7). PMID: 34358195.
      Citations: 11     
    2. Logunov DY, Dolzhikova IV, Shcheblyakov DV. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial - Authors' reply. Lancet. 2021 05 22; 397(10288):1883-1884. PMID: 33991474.
      Citations: 5     Fields:    Translation:Humans
    3. Kostin AI, Lundgren MN, Bulanov AY, Ladygina EA, Chirkova KS, Gintsburg AL, Logunov DY, Dolzhikova IV, Shcheblyakov DV, Borovkova NV, Godkov MA, Bazhenov AI, Shustov VV, Bogdanova AS, Kamalova AR, Ganchin VV, Dombrovskiy EA, Volkov SE, Drozdova NE, Petrikov SS. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma. Vox Sang. 2021 Jul; 116(6):665-672. PMID: 33734455.
      Citations: 1     Fields:    Translation:HumansPHPublic Health
    4. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 02 20; 397(10275):671-681. PMID: 33545094.
      Citations: 334     Fields:    Translation:HumansCTClinical Trials
    5. Logunov DY, Dolzhikova IV, Tukhvatullin AI, Shcheblyakov DV. Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply. Lancet. 2020 10 03; 396(10256):e54-e55. PMID: 32971043.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    6. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 09 26; 396(10255):887-897. PMID: 32896291.
      Citations: 271     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    7. Ozharovskaia TA, Zubkova OV, Dolzhikova IV, Gromova AS, Grousova DM, Tukhvatulin AI, Popova O, Shcheblyakov DV, Scherbinin DN, Dzharullaeva AS, Erokhova AS, Shmarov MM, Loginova SY, Borisevich SV, Naroditsky BS, Logunov DY, Gintsburg AL. Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein. Acta Naturae. 2019 Jan-Mar; 11(1):38-47. PMID: 31024747.
      Citations: 4